248
Views
38
CrossRef citations to date
0
Altmetric
Original Articles

Isoflavones Inhibit 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase in Vitro

, , &
Pages 428-432 | Received 14 Jul 2003, Accepted 10 Oct 2003, Published online: 22 May 2014

  • 1) Messina, M. J., Persky, V., Setchell, K. D. R., and Barnes, S., Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 21, 113–131 (1994).
  • 2) Liggins, J., Bluck, L. J. C., Runswick, S., Atkinson, C., Coward, W. A., and Bingham, S. A., Daidzein and genistein contents of vegetables. Br. J. Nutr., 84, 717–725 (2000).
  • 3) Messina, M., and Barnes, S., The roles of soy products in reducing cancer risk. J. Natl. Cancer Inst., 83, 541–546 (1991).
  • 4) Anthony, M. S., Soy and cardiovascular disease: cholesterol lowering and beyond. J. Nutr., 130, 662S–663S (2000).
  • 5) Goodman-Gruen, D., and Kitz-Silverstein, D., Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J. Nutr., 131, 1202–1206 (2001).
  • 6) Choi, Y. S., Kim, J. H., and Yoon, D. H., Effects of soy extract and sex on serum and liver lipid levels of the rat. Food Sci. Biotechnol., 11, 10–13 (2002).
  • 7) Alekel, D. L., Germain, A. S., Peterson, C. T., Hanson, K. B., Stewart, J. W., and Toda, T., Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am. J. Clin. Nutr., 72, 844–852 (2000).
  • 8) Somekawa, Y., Chiguchi, M., Ishibashi, T., and Aso, T., Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet. Gynecol., 97, 109–115 (2001).
  • 9) Messina, M., Soyfoods and soybean phyto-oestrogens (isoflavones) as possible alternative to hormone replacement therapy (HRT). Eur. J. Cancer, 36, 71S–72S (2000).
  • 10) Kapiotis, S., Hermann, M., Held, I., Seelos, C., Ehringer, H., and Gmeiner, B. M., Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler. Thromb. Vasc. Biol., 17, 2868–2874 (1997).
  • 11) Anderson, J. J. B., and Garner, S. C., The effects of phytoestrogens on bone. Nutr. Rev., 17, 1617–1632 (1997).
  • 12) Herman, C., Adlercreutz, T., Goldin, B. R., Gorbach, S. L., Höckerstedt, K. A. V., Watanabe, S., Hämäläinen, E. K., Markkanen, M. H., Mäkelä, T. H., Wahala, K. T., Hase, T. A., and Fotsis, T., Soybean phytoestrogen intake and cancer risk. J. Nutr., 125, 757S–770S (1995).
  • 13) Wangen, K. E., Duncan, A. M., Xu, X., and Kurzer, M. S., Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am. J. Clin. Nutr., 73, 225–231 (2001).
  • 14) Merz-Demlow, B. E., Duncan, A. M., Wangen, K. E., Xu, X., Carr, T. P., Phipps, W. R., and Kurzer, M. S., Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am. J. Clin. Nutr., 71, 1462–1469 (2000).
  • 15) Sung, J. H., Screening, identification and inhibition kinetics of HMG-CoA reductase inhibitors in Korean soybean paste. [dissertation], Seoul National University, Seoul, Koera (2002).
  • 16) Frimpong, K., Darnay, B. G., and Rodwell, V. W., Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase expressed in Escherichia coli: Production of homogeneous protein. Protein Expression Purif., 4, 337–344 (1993).
  • 17) Markham, K. R., Chemical methods used in flavonoids structure elucidation. In “Techniques of Flavonoid Identification”, ed. Markham, K. R., Academic Press, New York, pp. 62–71 (1982).
  • 18) Ikan, P., Acetogenins, flavonoids. In “Natural Products: A Laboratory Guide”, ed. Ikan, P., Academic Press, London, pp. 1–22 (1991).
  • 19) Breton, M., Precigoux, G., Courseille, C., and Hospital, M., Génisteine. Acta Crystallogr. B, 31, 921–923 (1975).
  • 20) Sirtori, C. R., Lovati, M. R., Manzoni, C., Monetti, M., Pazzucon, F., and Gatti, E., Soy and cholesterol reduction: Clinical experience. J. Nutr., 125, 598S–605S (1995).
  • 21) Caroll, K. K., and Kurowska, E. M., Soy consumption and cholesterol reduction: review of animal and human studies. J. Nutr., 125, 594S–597S (1995).
  • 22) Potter, S. M., Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr. Rev., 56, 231–235 (1998).
  • 23) Endo, A., Kuroda, M., and Tanzawa, K., Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett., 72, 323–326 (1976).
  • 24) Adlercreutz, H., Fotsis, T., Watanabe, S., Lampe, J., Wahala, K., Makela, T., and Hase, T., Determination of lignans and isoflavonoids in plasma by isotope dilution GC/MS. Cancer Detect. Prevent., 18, 259–271 (1994).
  • 25) Xu, X., Harris, K. S., Wang, H. J., Murphy, P. A., and Hendrich, S., Bioavailability of soybean isoflavones depends upon gut microflora in women. J. Nutr., 125, 2307–2315 (1995).
  • 26) Morton, M. S., Matos-Ferreira, A., Abranches-Monteiro, L., Correia, R., Blacklock, N., Chan, P. S. F., Cheng, C., Lloyd, S., Chieh-ping, W., and Griffiths, K., Measurement and metabolism of isoflavonoids and lignans in the human male. Cancer Lett., 114, 145–151 (1997).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.